Curis Inc

-0.01 (-2.44%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)49.44M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$2.54 Million
Adjusted EPS-$0.12
See more estimates
10-Day MA$0.45
50-Day MA$0.61
200-Day MA$0.69
See more pivots

Curis Inc Stock, NASDAQ:CRIS

Building C, 128 Spring Street, Lexington, Massachusetts 02421
United States of America
Phone: +1.617.503.6500
Number of Employees: 51


Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.